Edwards Lifesciences (NYSE:EW) Hits New 12-Month High – Here’s What Happened

Edwards Lifesciences Corporation (NYSE:EW)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $90.21 and last traded at $90.44, with a volume of 419047 shares traded. The stock had previously closed at $86.95.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Royal Bank Of Canada reiterated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Wednesday, April 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Trading Up 4.2%

The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $83.70 and a 200-day simple moving average of $83.16. The firm has a market cap of $52.19 billion, a P/E ratio of 48.30, a P/E/G ratio of 2.15 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the prior year, the company earned $0.64 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 81,038 shares of company stock worth $6,683,255 over the last three months. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the stock. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $25,000. Kemnay Advisory Services Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth $28,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.